Drugging Dynamic Proteins
Half of all human proteins are highly flexible and cannot be systematically drugged with current technologies which can only generate “photos”. Resonate Bio’s hybrid AI-NMR technology can generate “movies” of drugs binding to their target proteins. This unlocks structure-based drug design for dynamic disease-causing proteins.
Transforming Structure-Based Drug Design
Scientists use technologies such as X-ray crystallography to obtain “photos” of disease causing proteins with drug molecules bound like a lock and key. This allows them to see where every atom is positioned, enabling them to design the perfectly fitting drug (key) for the disease causing protein (lock) being targeted. This technology has transformed drug discovery for rigid proteins turning many of them from “undruggable” to drugged. In order to drug “undruggable” flexible proteins a technology capable of taking “movies” at the atomic level is required.
Approved drugs transformed by structure
Viracept bound to HIV Protease
Discovered by Agouron Pharmaceuticals in San Diego USA and FDA approved in 1997
Zanamavir bound to neuraminidase
Discovered by Biota Holdings in Melbourne Australia and FDA approved in 1999
Venetoclax bound to BCL2
Discovered by Abbott in Illinois USA and FDA approved in 2016
Sotorasib bound to KRAS-G12C
Discovered by Amgen at Thousand Oaks USA and FDA approved in 2021
Resonate News
Resonate Bio and University of Vienna Launch Strategic Collaboration to Advance AI-NMR Drug Discovery
Resonate Bio Secures Austria Wirtschaftsservice (AWS) Deep Tech Seed Financing to Advance AI-Driven NMR Platform — and Bets on Itself with First Internal Therapeutics Program